Holen Sie sich die Stockscreener-App
30.10
2.14%
0.63
Handel nachbörslich:
30.12
0.02
+0.07%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ALKS?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$29.47
Offen:
$29.81
24-Stunden-Volumen:
1.33M
Relative Volume:
0.86
Marktkapitalisierung:
$5.09B
Einnahmen:
$1.51B
Nettoeinkommen (Verlust:
$333.35M
KGV:
15.44
EPS:
1.95
Netto-Cashflow:
$315.22M
1W Leistung:
+5.61%
1M Leistung:
+1.31%
6M Leistung:
+21.22%
1J Leistung:
+7.89%
1-Tages-Spanne:
$29.68
$30.15
1-Wochen-Bereich:
$28.28
$30.15
52-Wochen-Spanne:
$22.90
$32.88
Alkermes Plc Stock (ALKS) Company Profile
Firmenname
Alkermes Plc
Sektor
Telefon
00-353-1-772-8000
Adresse
CONNAUGHT HOUSE, DUBLIN 4
Vergleichen Sie ALKS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
30.10 | 5.09B | 1.51B | 333.35M | 315.22M | 1.95 |
|
ZTS
Zoetis Inc
|
167.53 | 75.58B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.24 | 41.78B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.10 | 41.53B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
21.82 | 24.72B | 16.77B | -959.00M | 1.37B | -0.85 |
|
NBIX
Neurocrine Biosciences Inc
|
145.88 | 14.77B | 2.24B | 385.90M | 440.10M | 3.73 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-05 | Hochstufung | Stifel | Hold → Buy |
| 2024-06-17 | Eingeleitet | TD Cowen | Buy |
| 2024-03-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-02-20 | Herabstufung | UBS | Neutral → Sell |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-10-24 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-10-17 | Eingeleitet | UBS | Neutral |
| 2022-11-03 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-14 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-08-16 | Eingeleitet | Piper Sandler | Neutral |
| 2022-04-22 | Fortgesetzt | Goldman | Buy |
| 2022-04-20 | Eingeleitet | Goldman | Buy |
| 2022-01-27 | Hochstufung | Cantor Fitzgerald | Hold → Overweight |
| 2021-12-01 | Eingeleitet | Citigroup | Neutral |
| 2021-10-07 | Hochstufung | Jefferies | Hold → Buy |
| 2021-09-02 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-10-15 | Hochstufung | Mizuho | Neutral → Buy |
| 2020-07-30 | Herabstufung | Goldman | Neutral → Sell |
| 2020-02-14 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2020-02-14 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-02-14 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2020-01-31 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2019-09-05 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2019-07-15 | Hochstufung | Goldman | Sell → Neutral |
| 2019-05-31 | Eingeleitet | H.C. Wainwright | Neutral |
| 2019-05-01 | Herabstufung | Citigroup | Buy → Neutral |
| 2018-12-19 | Herabstufung | Goldman | Neutral → Sell |
| 2018-12-14 | Eingeleitet | Wolfe Research | Underperform |
| 2018-12-13 | Herabstufung | Credit Suisse | Outperform → Underperform |
| 2018-11-05 | Eingeleitet | Piper Jaffray | Neutral |
| 2018-08-07 | Eingeleitet | Stifel | Hold |
| 2018-06-21 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2018-06-06 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2018-05-16 | Hochstufung | Citigroup | Neutral → Buy |
| 2018-05-11 | Eingeleitet | BofA/Merrill | Buy |
Alle ansehen
Alkermes Plc Aktie (ALKS) Neueste Nachrichten
With nearly $1B in the bank, Alkermes is on the hunt for deals - The Business Journals
Short Interest in Alkermes plc (NASDAQ:ALKS) Drops By 14.1% - MarketBeat
Benign Growth For Alkermes plc (NASDAQ:ALKS) Underpins Its Share Price - Simply Wall St
(ALKS) Proactive Strategies - Stock Traders Daily
Alkermes plc (NASDAQ:ALKS) Holdings Trimmed by JPMorgan Chase & Co. - MarketBeat
Zacks Research Reduces Earnings Estimates for Alkermes - MarketBeat
What is Zacks Research's Forecast for Alkermes Q2 Earnings? - MarketBeat
Alkermes plc (NASDAQ:ALKS) Receives $36.00 Average PT from Brokerages - MarketBeat
Alkermes to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Malaysian Reserve
Alkermes CEO to Present Corporate Strategy at J.P. Morgan Healthcare Conference 2025 - StockTitan
Alkermes to Report Third Quarter Financial Results on October 24, 2024 - Quantisnow
Declining Stock and Solid Fundamentals: Is The Market Wrong About Alkermes plc (NASDAQ:ALKS)? - Yahoo Finance
Alkermes plc (NASDAQ:ALKS) Sees Large Decrease in Short Interest - MarketBeat
Principal Financial Group Inc. Has $24.57 Million Position in Alkermes plc (NASDAQ:ALKS) - MarketBeat
(ALKS) On The My Stocks Page - Stock Traders Daily
Alkermes plc (NASDAQ:ALKS) Stake Boosted by Sanctuary Advisors LLC - MarketBeat
Expansion Therapeutics Names Elliot Ehrich, MD, Chief Medical Officer - Marketscreener.com
Alkermes pays off and terminates major credit agreement By Investing.com - Investing.com Canada
2025 will be a big year for Mural Oncology's drugs in development - The Business Journals
Alkermes pays off and terminates major credit agreement - Investing.com
Alkermes Prepares for New Flexibility Post Credit Termination - TipRanks
Tidal Investments LLC Takes Position in Alkermes plc (NASDAQ:ALKS) - MarketBeat
Geode Capital Management LLC Sells 60,037 Shares of Alkermes plc (NASDAQ:ALKS) - MarketBeat
We Think Alkermes (NASDAQ:ALKS) Can Stay On Top Of Its Debt - Simply Wall St
Wilmington Savings Fund Society FSB Invests $582,000 in Alkermes plc (NASDAQ:ALKS) - MarketBeat
Barclays PLC Boosts Holdings in Alkermes plc (NASDAQ:ALKS) - MarketBeat
Alkermes To Take Part In The Fourth Annual Evercore ISI Healthconx Conference - Environmental Expert
Opioid Use Disorder Market: Share, Key Trends, Growth Drivers, - openPR
When (ALKS) Moves Investors should Listen - Stock Traders Daily
Fmr LLC Has $9.71 Million Stake in Alkermes plc (NASDAQ:ALKS) - MarketBeat
State Street Corp Lowers Stake in Alkermes plc (NASDAQ:ALKS) - MarketBeat
Alkermes plc (NASDAQ:ALKS) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Alkermes' EVP Craig Hopkinson sells shares worth $1.96 million By Investing.com - Investing.com South Africa
Frazier Life Sciences Management L.P. Acquires New Stake in Alkermes plc (NASDAQ:ALKS) - MarketBeat
Alkermes director Cato Laurencin sells $85,708 in stock - Investing.com India
Alkermes director Cato Laurencin sells $85,708 in stock By Investing.com - Investing.com Canada
Alkermes' EVP Craig Hopkinson sells shares worth $1.96 million - Investing.com
Wellington Management Group LLP Sells 1,696,507 Shares of Alkermes plc (NASDAQ:ALKS) - MarketBeat
Alkermes plc (NASDAQ:ALKS) Stake Lifted by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat
Insider Sell: Craig Hopkinson Sells 9,221 Shares of Alkermes PLC (ALKS) - GuruFocus.com
Alkermes' chief medical officer sells $290,461 in stock - Investing.com India
Alkermes' chief medical officer sells $290,461 in stock By Investing.com - Investing.com UK
Insider Sell: Craig Hopkinson Sells 14,349 Shares of Alkermes PL - GuruFocus.com
RTW Investments LP Sells 402,955 Shares of Alkermes plc (NASDAQ:ALKS) - MarketBeat
BNP Paribas Financial Markets Buys 63,939 Shares of Alkermes plc (NASDAQ:ALKS) - MarketBeat
Alkermes EVP and chief medical officer sells shares worth $441,550 By Investing.com - Investing.com Canada
Alkermes EVP and chief medical officer sells shares worth $441,550 - Investing.com
Finanzdaten der Alkermes Plc-Aktie (ALKS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):